Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy.
Introduction and Objectives. Neutrophil-to-lymphocyte ratio (NLR) has been suggested to be a simple marker of the systemic inflammatory response in critical care patients. We previously assessed the utility of NLR as a biomarker to predict tumor recurrence and cancer death in bladder cancer patients who underwent radical cystectomy. In this study, we evaluated the prognostic impact of NLR in bladder cancer patients who received gemcitabine and nedaplatin (GN) chemotherapy.Methods. A total of 23 patients who received GN chemotherapy for advanced bladder cancer were enrolled in this study. The cut-off point of NLR according to the sensitivity and specificity levels was derived from the area under receiver operator characteristics (AUROC) curve plotted for disease progression or overall mortality.Results. The NLR cut-off point was determined as 4.14 for both tumor progression and overall mortality. Median progression-free survival (PFS)/overall survival (OS) in the higher NLR group (NLR ≥ 4.14) and lower NLR group (NLR < 4.14) were 194/468 days versus 73/237 days, respectively. Kaplan-Meier analysis showed that higher NLR significantly correlated with poorer PFS (p= 0.011) and OS (p= 0.045).Conclusions. NLR may serve as a new biomarker to predict responses to GN-based chemotherapy in advanced bladder cancer patients and/or their prognosis.
Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Shinji
S
Ohtake
Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan; Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
Takashi
0000-0002-7049-3379
T
Kawahara
Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Ryo
R
Kasahara
Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Hiroki
H
Ito
Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Kimito
0000-0003-4110-7130
K
Osaka
Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
Yusuke
Y
Hattori
Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
Jun-Ichi
JI
Teranishi
Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Kazuhide
K
Makiyama
Department of Urology, Yokohama Sakae Kyosai Hospital, Yokohama, Japan.
Nobuhiko
N
Mizuno
Department of Urology, Hiratsuka Kyosai Hospital, Hiratsuka, Japan.
Susumu
S
Umemoto
Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
Yasuhide
Y
Miyoshi
Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Noboru
N
Nakaigawa
Departments of Pathology and Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hiroshi
0000-0003-4437-4015
H
Miyamoto
Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Masahiro
M
Yao
Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
Hiroji
0000-0003-3775-2671
H
Uemura
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001772:Blood Cell Count; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008214:Lymphocytes / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000473:pathology*; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D000093542:Gemcitabine
D014408:Biomarkers, Tumor; D009944:Organoplatinum Compounds; D003841:Deoxycytidine; C053989:nedaplatin; D000093542:Gemcitabine